R&D Systems™ Human VEGF 165 Biotinylated, Carrier-Free Recombinant Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Manufacturer: R&D Systems™ BT293010/CF
DescriptionThe Recombinant Human VEGF 165 Biotinylated Protein is derived from Sf 21 (baculovirus). The Recombinant Human VEGF 165 Biotinylated Protein has been validated for the following applications: Bioactivity.
|Spodoptera frugiperda, Sf 21 (baculovirus)-derived Ala27-Arg191|
|Theoretical M.W.: 19kDa|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.|
|MVCD1, VAS, vascular endothelial growth factor A, Vascular permeability factor, Vasculotropin, VEGFA, VEGF-A, VEGFMGC70609, VPF, VPFvascular endothelial growth factor|
|>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining|
|Spodoptera frugiperda,Sf 21 (baculovirus)-derived human VEGF protein Ala27-Arg191|
|<0.10 EU per 1μg of the protein by the LAL method.|
|Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED50 for this effect is typically 1-6ng/mL.|
|Reconstitute at 100μg/mL in 4mM HCl.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok